Search Results for “EU” – Page 394 – media

FEops closes €6m Series B financing

FEops, a leader in personalized computer modeling for structural heart interventions, announced today that it has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV.
- Source: medicaldevices-business-review
- 623
- September 26, 2017
heart investment Market Views Series
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients

Merck, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
- Source: Merck
- 547
- September 25, 2017
adenocarcinoma anti-PD-1 GEJ keytruda New Approvals
China’s Import and Export Report of Home Medical Equipment

Home medical equipment are safe and reliable, user-friendlyand portable medical devices used outside of hospitals for the purpose of detection, treatment, health care and rehabilitation.
- Source: Ddu
- 2,377
- September 25, 2017
Home medical equipment Market Reports
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 702
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
The world is running out of antibiotics, WHO says

(CNN)Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published Tuesday. Adding to the concern: It is likely that the speed of increasing resistance will outpace the slow drug development process.
- Source: edition
- 660
- September 22, 2017
antibiotics Researches WHO
China’s Import and Export Market of Obstetrics and Gynecology Equipment

Development of technology over the past couple of decades has led to societal and cultural development which in turn has resulted in awareness of issues such as the importance of women’s health. With vast improvements taking place in this field, obstetrics and gynecology equipment has experienced major changes.
- Source: Ddu
- 1,280
- September 20, 2017
export gynecology import Market Reports obstetrics
UOW researchers secure grant to develop new medical device for bedside brain monitoring

A University of Otago, Wellington (UOW) team has been awarded an MBIE Endeavour grant to develop a non-invasive and cost-effective device to diagnose and treat stroke and other brain injuries.
- Source: medicaldevices-business-review
- 699
- September 20, 2017
brain non-invasive Researches stroke
Centinel Spine acquires Prodisc assets from J&J’s DePuy Synthes

Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
- Source: Massdevice
- 666
- September 20, 2017
acquisition Market Views Prodisc
AbbVie Announces Positive Topline Results from Phase 3 MURANO study

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA/VENCLYXTO (Venetoclax) Tablets in combination with Rituxan® (rituximab) met its primary endpoint.
- Source: news.abbvie
- 663
- September 20, 2017
Clinical Trials CLL Phase rituximab Venetoclax
FDA approves first cancer biosimilar

The US Food and Drug Administration(FDA) has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.
- Source: Pharmatimes
- 685
- September 18, 2017
biosimilar cancer FDA New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.